Invega tablets 6 mg. №28

Description

Invega Composition
active substance: paliperidone;

1 tablet contains paliperidone 6 mg;

Invega Excipients:

polyethylene oxide 200K;
povidone, stearic acid butylhydroxytoluene (E321) sodium chloride, cellulose acetate;
hypromellose;
hydroxyethyl cellulose;
polyethylene glycol 3350;
titanium dioxide (E171) polyethylene oxide 7000K;
carnauba wax;
iron oxide black (E172) isopropyl alcohol, propylene glycol;
iron oxide red (E172) (Tablets of 3 mg – lactose monohydrate, glycerin triacetate;
iron oxide yellow (E172) tablets of 6 mg and 9 mg – polyethylene glycol 400 tablets of 6 mg – iron oxide yellow (E172)).
Dosage form
Sustained-release film-coated tablets.

Basic physical and chemical properties:

6 mg – capsule-like beige tablets with the inscription “PAL 6” on one side

The holes on the surface of 6 mg tablets may be barely visible.

Invega Pharmacotherapeutic group
Antipsychotic drugs. Other antipsychotics. Paliperidone.

ATX code N05A X13.

Pharmacodynamics
Invega® contains a racemic mixture of (+) and (-) – paliperidone.

Mechanism of action

Paliperidone is a selective blocking agent of the effects of monoamines, the pharmacological properties of which differ from traditional antipsychotics. Paliperidone strongly binds to serotonin 5-HT 2 and dopamine D2 receptors. In addition, paliperidone is an antagonist of alpha 1 adrenergic receptors and, to a lesser extent, H1 and alpha2 adrenergic receptors. The pharmacological activity of the (+) and (-) – enantiomers of paliperidone is qualitatively and quantitatively the same.

Paliperidone does not bind to cholinergic receptors. Although paliperidone is a potent D2 receptor antagonist and is thought to reduce the positive symptoms of schizophrenia, it induces catalepsy and decreased motor function to a lesser extent than traditional antipsychotics. The predominant central antagonism to serotonin can reduce the property of paliperidone to cause adverse reactions of extrapyramidal origin.

Indications
Treatment of schizophrenia in adults and children over 15 years of age.

Treatment of schizoaffective disorders in adults.

Contraindications
Hypersensitivity to the active substance, to risperidone or to any of the auxiliary components of the drug.

Overdose
In general, the expected symptoms of paliperidone overdose are manifested by an increase in the pharmacological effects of this drug, namely: drowsiness, sedation, tachycardia, arterial hypotension, prolongation of the QT interval, extrapyramidal symptoms. In case of overdose, bi-directional ventricular tachycardia and ventricular fibrillation were observed. In case of acute overdose, the possibility of action of several drugs should be considered.